Literature DB >> 30844722

Role of EZH2 in cell lineage determination and relative signaling pathways.

Aalia Batool1, Cheng Jin2, Yi-Xun Liu2.   

Abstract

Enhancer of zeste homolog 2 (EZH2), a catalytic component of polycomb repressive complex 2 (PRC2), epigenetically regulates chromatin structure and gene expression through trimethylation at histone H3K27 and recruitment of DNA methyltransferases for gene silencing. Despite extensive studies of the role of EZH2 in cancer progression and malignancy, increasing evidences suggest that EZH2 plays a critical role in stem cells renewal, maintenance, and differentiation into specific cell lineages. Here, we reviewed the update information regarding how EZH2 contributes to stem cell maintenance and cell lineage determination (including gonadogenesis, neurogenesis, myogenesis, osteogenesis, hematopoiesis, lymphopoiesis, adipogenesis, epidermal differentiation and hepatogenesis), and the regulation of EZH2 by phosphorylation and different signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30844722     DOI: 10.2741/4760

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  6 in total

Review 1.  The pathological and therapeutic roles of mesenchymal stem cells in preeclampsia.

Authors:  Sanshan Jin; Canrong Wu; Ming Chen; Dongyan Sun; Hua Zhang
Journal:  Front Med (Lausanne)       Date:  2022-07-28

2.  The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.

Authors:  Shi-Yi Wu; Zhao-Yu Xie; Lu-Yu Yan; Xiao-Fang Liu; Yue Zhang; Da-An Wang; Jie Dong; Hong-Tao Sun
Journal:  BMC Immunol       Date:  2022-06-04       Impact factor: 3.594

Review 3.  EZH2: a novel target for cancer treatment.

Authors:  Ran Duan; Wenfang Du; Weijian Guo
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

4.  EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.

Authors:  Hao Gong; Yongwen Li; Yin Yuan; Weiting Li; Hongbing Zhang; Zihe Zhang; Ruifeng Shi; Minghui Liu; Chao Liu; Chen Chen; Hongyu Liu; Jun Chen
Journal:  BMC Cancer       Date:  2020-12-04       Impact factor: 4.430

5.  miR-101-3p Serves as a Tumor Suppressor for Renal Cell Carcinoma and Inhibits Its Invasion and Metastasis by Targeting EZH2.

Authors:  Yunze Dong; Yuchen Gao; Tiancheng Xie; Huan Liu; Xiangcheng Zhan; Yunfei Xu
Journal:  Biomed Res Int       Date:  2021-07-07       Impact factor: 3.411

Review 6.  EZH2 as a Potential Target for NAFLD Therapy.

Authors:  Hyun Jung Lim; Mirang Kim
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.